Canadian life sciences company, Avivagen, claims to be developing two disruptive technologies. The first is a natural product designed to replace antibiotic use in livestock feeds and the second is a medication-based non-surgical sterilization process for female animals.
Avivagen is currently using its antibiotic replacement (OxC-beta) in two pet supplements (Vivamune and Oximunol) and is looking to expand its use in livestock destined for consumption.
About Avivagen Inc.
Avivagen Inc. is a publicly-listed life sciences company trading on the TSX Venture Exchange under the ticker symbol “VIV” and on OTC Pink as “CHEXF.” The Company’s goal is to develop and deliver scientifically-proven solutions that benefit companion and production animals by employing natural mechanisms for maintaining good health. Target markets include Livestock Productivity and Pet Wellness.
Avivagen is based in partnership facilities of the National Research Council of Canada (NRC) – in Ottawa, Ontario and Charlottetown, Prince Edward Island.
No comments:
Post a Comment